<DOC>
	<DOCNO>NCT02390648</DOCNO>
	<brief_summary>Breast cancer patient receive AC regimen chemotherapy ( Doxorubicin + Cyclophosphamide ) nausea score 40/100 VAS vomit first second cycle chemotherapy recruit . The patient meet eligibility criterion provide informed consent randomise receive either Ginger capsule ( 500 mg ) placebo take twice day mouth first 5 day chemotherapy cycle . The study drug switch subsequent cycle ( i.e . patient receive Ginger capsule receive placebo vice versa ) . The primary outcome nausea score vomit first 5 day chemotherapy cycle receive study drug .</brief_summary>
	<brief_title>Efficacy Ginger Adjunctive Prophylaxis Chemotherapy-induced Nausea Vomiting</brief_title>
	<detailed_description />
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<criteria>Histologically cytologically confirm breast cancer patient Received AC regimen chemotherapy ( Doxorubicin + Cyclophosphamide ) nausea score least 40/100 VAS vomit Expect receive least 2 cycle AC regimen chemotherapy Provide inform consent Pregnancy lactation Has nausea vomit 24 hour chemotherapy Has cause nausea vomit eg . brain metastasis , gut obstruction , hepatitis recent abdominal pelvic irradiation within 1 week chemotherapy Received chemotherapy regimen AC regimen Allergic intolerance ginger</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>